Berlin, 2018-03-27 - NBE-Therapeutics presented at 2018 World ADC congress

Ulf Grawunder, CEO of NBE-Therapeutics, presented at Hanson-Wade's 8th Annual World-ADC summit-Europe in Berlin at the end of March

NBE-Therapeutics, represented by its CEO, Ulf Grawunder, provided an update on the company's ADC development activities at the 8th international Wolrd ADC summit Europe, taking place in Berlin from March 26-28, 2018. NBE-Therapeutics 30 minute presentation was entitled "Preclinical Validation of Site-Specifically Conjugated ADCs with Potent Anthracycline Payloads in Solid & Hemtologic Tumor Models". The presentation was scheduled in March 27, 14:30 p.m. in the session "Antibody Drug Comjugates: Design & Selection of Linker, Payload & Conjugation Chemistry". Hanson-Wade's World ADC congress series is one of the leading events in the field of ADC product or technology development. This year's World ADC summit took place in the Maritim proArte Hotel in Berlin-Mitte, Germany. The link to the conference web-site is:

All Meetings/ Conferences